Loading...
TAOX
XNAS
Market cap12mUSD
Nov 20, Last price  
1.55USD
1D
-10.40%
1Q
-59.84%
IPO
-98.20%
Name

Synaptogenix Inc

Chart & performance

D1W1MN
XNAS:TAOX chart
P/E
—
P/S
41.70
EPS
—
Vol. 1Y
98.50%
Shs. 5Y
130.88%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
299k
0000000299,061
Net income
-29m
L+125.06%
-11,022,286-14,756,043-14,249,984-12,604,087-5,458,067-6,038,504-12,768,549-28,737,448
CFO
-6m
L+30.94%
-7,696,771-11,886,809-8,102,398-8,710,725-11,211,245-5,173,209-4,883,988-6,395,010

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

TAO Synergies Inc. operates as a biopharmaceutical company currently in the clinical development stage. It is dedicated to advancing a bryostatin-1 therapeutic platform, specifically designed to combat Alzheimer's and various other neurodegenerative and cognitive disorders. Beyond its drug development efforts, the firm is also diversifying its treasury strategy, with a new approach centered on the management of digital assets, primarily focusing on the acquisition and 'staking' of TAO cryptocurrency.

Key people

Executive Chairman of the Board · since 2025
Chief Financial Officer, Executive Vice President, Treasurer, Secretary · since 2021
Alan Tuchman
Chief Medical Officer · since 2025
Robert Ephron
Director · since 2025
Independent Director · since 2016
William Singer
Independent Vice Chairman of the Board · since 2019
IPO date
Dec 07, 2020
Employees
5
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT